Could weight-loss drugs hit restaurant sales? UBS weighs in.

UBS analysts predict a significant sales headwind for the restaurant industry, particularly quick-service and casual dining, due to the increasing use of GLP-1 weight-loss drugs. A UBS survey revealed that 40% of users altered eating habits, with nearly half reducing daily caloric intake by 251-800 calories and over 50% consuming smaller portions, leading to a "notable headwind" for fast food and potential shifts in menu offerings towards healthier options. This trend, driven by popular drugs like Wegovy and Mounjaro, is also expected to impact sales of items such as ice cream and chocolate.

Analysis

UBS analysts project a significant sales headwind for the restaurant industry, particularly quick-service and casual dining, driven by the increasing adoption of GLP-1 weight-loss drugs. A recent UBS survey of 500 respondents revealed that 40% altered their eating habits while on these medications, with nearly half reducing daily caloric intake by 251-800 calories.

Over 50% of users reported eating smaller portions, and some were skipping meals, specifically 30% for breakfast, 20% for lunch, and 10% for dinner. Crucially, more than two-thirds indicated eating less fast food, signaling a "notable headwind" for quick-service options and potential pressure on dessert categories like ice cream and chocolate.

This trend underscores the growing influence of GLP-1 agonists, such as Wegovy, Mounjaro, and Zepbound, which have become immensely popular obesity treatments, significantly benefiting pharmaceutical giants like Novo Nordisk and Eli Lilly. The drugs' broader health applications, extending beyond weight loss, further solidify their market presence.

The analysis suggests a cautious outlook for certain restaurant segments, prompting potential shifts in menu offerings towards healthier options to align with changing consumer demand. This dynamic creates a bifurcated market impact, negatively affecting specific consumer discretionary sectors while bolstering the pharmaceutical innovators.

Key Decisions for Investors

• Investors should evaluate exposure to quick-service and casual dining restaurant chains, particularly those with less healthy offerings or high breakfast sales, for potential sales deceleration
• Consider monitoring the sales performance of companies in dessert categories like ice cream and chocolate for signs of reduced consumption
• Assess the growth trajectories of pharmaceutical companies like Novo Nordisk and Eli Lilly, which are direct beneficiaries of the expanding GLP-1 market
• Watch for strategic shifts in the restaurant industry, such as menu adaptations towards healthier options, as companies respond to evolving consumer preferences